Evaluation of the Enhanced Atellica® IM SARS-CoV-2 IgG (sCOVG) Assay White Paper 

Demonstrates strong relationship between the Atellica IM sCOVG Assay index value and neutralization titer

Whitepaper Evaluation of the Enhanced Atellica® IM SARS-CoV-2 IgG(sCOVG) Assay White Paper

The enhanced Atellica® IM SARS-CoV-2 IgG (sCOVG)* Assay demonstrates analytical performance capable of measuring patient IgG antibody response to the S1 RBD antigen with accuracy and precision and is acceptable for quantifying an individual’s immune response, including production of neutralizing antibodies, and identifying an individual’s immunocompetence to the SARS-CoV-2 virus.

Learn more about the sCOVG assay performance.